share_log

EF Hutton Initiates Coverage On Acasti Pharma With Buy Rating, Announces Price Target of $2.5

EF Hutton Initiates Coverage On Acasti Pharma With Buy Rating, Announces Price Target of $2.5

EF Hutton 以买入评级开始对阿卡斯蒂制药进行报道,宣布目标价为2.5美元
Benzinga Real-time News ·  2022/12/19 20:12

EF Hutton analyst Constantine Davides initiates coverage on Acasti Pharma (NASDAQ:ACST) with a Buy rating and announces Price Target of $2.5.

EF Hutton分析师康斯坦丁·戴维斯对Acasti Pharma(纳斯达克:ACST)发起买入评级,并宣布目标价为2.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发